Skip to main content

Table 2 Efficacy of rituximab and 2-CdA in the WSU-WM-SCID xenograft model

From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies

Agent

Dose/(mg/kg), schedule

Route

Mice

T/C (%)

T-C Days

Log 10kill

Cure

Control

Diluent, QD × 5

i.v.

8

100

0

0

0/8

Rituximab

150 mg, QD × 5

i.v.

8

30

13

1.9

0/8

2-CdA

30 mg, QD × 5

s.c.

8

36.9

14

1.33

0/8

(RTX + 2-CdA)

(150 + 30),QD × 5

(i.v. + s.c.)

     

Diluent

Diluent, QD × 5

i.v.

8

16.9

N/A

N/A

8/8

(RTX + 2-CdA)

(150 + 30),QD × 5

(i.v. + s.c.)